{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:14:43Z","timestamp":1793016883781,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020333","name":"Guerbet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jvir.2023.08.039","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T11:36:37Z","timestamp":1693395397000},"page":"2147-2154.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-1922","authenticated-orcid":false,"given":"Hannah C.","family":"Hund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4926-2135","authenticated-orcid":false,"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8082-0532","authenticated-orcid":false,"given":"Lea","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-0752","authenticated-orcid":false,"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-2262","authenticated-orcid":false,"given":"Andrew S.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Golzarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-7388","authenticated-orcid":false,"given":"Ripal T.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-2883","authenticated-orcid":false,"given":"Daniel B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2023.08.039_bib1","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy","volume":"28","author":"Gaba","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2023.08.039_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Al Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jvir.2023.08.039_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000480208","article-title":"Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2","volume":"35","author":"Arizumi","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.jvir.2023.08.039_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2023.08.039_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2023.08.039_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s11605-023-05712-x","article-title":"Salvage locoregional therapy following progression after radiotherapy for hepatocellular carcinoma is associated with improved outcomes","author":"Lin","year":"2023","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.jvir.2023.08.039_bib8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jvir.2023.08.039_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvir.2023.08.039_bib10","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jvir.2023.08.039_bib11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2023.08.039_bib12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s10147-022-02166-0","article-title":"New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma","volume":"27","author":"Kudo","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jvir.2023.08.039_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2023.08.039_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2023.08.039_bib15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jvir.2019.07.020","article-title":"Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for hepatocellular carcinoma","volume":"30","author":"Das","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib16","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00270-017-1739-5","article-title":"Safety and efficacy of transarterial radioembolisation in patients with intermediate or advanced stage hepatocellular carcinoma refractory to chemoembolisation","volume":"40","author":"Klompenhouwer","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00270-023-03388-z","article-title":"Boosted-dose yttrium-90 radiation segmentectomy or lobectomy for hepatocellular carcinoma refractory to prior transarterial embolization or chemoembolization: a single institution retrospective case series","volume":"46","author":"Srinivas","year":"2023","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib18","series-title":"NCCN clinical practice guidelines in oncology(NCCN Guidelines\u00ae) for hepatocellular carcinoma, version 1.2023","year":"2023"},{"key":"10.1016\/j.jvir.2023.08.039_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions","volume":"28","author":"Padia","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jvir.2022.11.036","article-title":"Radioembolization for intermediate-stage hepatocellular carcinoma maintains liver function and permits systemic therapy at progression","volume":"34","author":"Ranganathan","year":"2023","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jvir.2019.08.033","article-title":"Toxicity and survival of hepatocellular carcinoma patients with hepatitis B infection treated with yttrium-90 radioembolization: an updated 15-year study","volume":"31","author":"Gao","year":"2020","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2023.08.039_bib22","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2023.08.039_bib23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2023.08.039_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2023.08.039_bib25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.sla.0000245829.00977.45","article-title":"A\u00a0randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma","volume":"245","author":"Lo","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2023.08.039_bib26","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2023.08.039_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2023.08.039_bib30","author":"He"},{"key":"10.1016\/j.jvir.2023.08.039_bib31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/cancers12061557","article-title":"Personalised dosimetry in radioembolisation for HCC: impact on clinical outcome and on trial design","volume":"12","author":"Garin","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044323006504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044323006504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:10:10Z","timestamp":1760940610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044323006504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1051044323006504"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2023.08.039","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2023.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2023","name":"copyright","label":"Copyright"}]}}